Clinical trials
Terminated Metabolic Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 40 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| HemoShear Therapeutics | 2 |
| Hope Pharmaceuticals | 2 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| SwanBio Therapeutics, Inc. | 2 |
| Alberta Children's Hospital | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Baylor College of Medicine | 1 |
| Bellicum Pharmaceuticals | 1 |
| CRISPR Therapeutics AG | 1 |
| CeQur Corporation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Metabolic Diseases | 40 |
| Glucose Metabolism Disorders | 9 |
| Diabetes Mellitus | 8 |
| Genetic Diseases, Inborn | 7 |
| Obesity | 7 |
| Endocrine System Diseases | 6 |
| Metabolism, Inborn Errors | 5 |
| Cardiovascular Diseases | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Brain Diseases, Metabolic, Inborn | 3 |
Trials
Showing 51 to 40 of 40. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.